OncoCyte Q4 2021 Earnings Preview (NASDAQ:OCX)

10:35pm, Wednesday, 09'th Mar 2022 Seeking Alpha
OncoCyte (NASDAQ:OCX) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.09 (flat Y/Y) and the consensus…
IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will release its financial and operating results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the close of the U.S. financial markets. The Company will host a conference call on Thursday, March 10, 2022, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Tivity Health (TVTY) Lags Q4 Earnings Estimates

11:40pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Tivity Health (TVTY) delivered earnings and revenue surprises of -21.05% and 0.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LHC Group (LHCG) Q4 Earnings Lag Estimates

10:25pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
LHC (LHCG) delivered earnings and revenue surprises of -4.55% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates

10:45pm, Thursday, 17'th Feb 2022 Zacks Investment Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.34% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Following agreement with Thermo Fisher, Oncocyte shares plunge 24%

08:52pm, Wednesday, 19'th Jan 2022 Seeking Alpha
Following an after-the-closing bell announcement yesterday of a development and co-marketing agreement with Thermo Fisher Scientific, shares of Oncocyte fell sharply today.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH) announced an upward revision
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH ) announced an upward revision to its 2021 net revenue guidance from 30 million Danish Krone to 40 million Danish Krone ($4.6 million - $6.1 million) to 35 million Danish Krone to 37 million Danish Krone ($5.3 million-$5.6 million). The company also narrowed its operating loss outlook. The company noted that the improved financial outlook for 2021 is mainly driven by increased visibility on net revenues from the use of arimoclomol in the Early Access Program in France and lower-than-expected operating expenses due to strict cost management. The stock was surging up 7.66% to $ 2.39 in premarket trading. Galapagos'' Filgotinib Gets U.K. Regulatory Nod For Treating Ulcerative Colitis Galapagos NV (NASDAQ: GLPG ) announced that the Medicines and Healthcare products Regulatory Agency has granted a marketing authorization for Jyseleca (filgotinib 200mg tablets), as a new treatment for ulcerative colitis in Great Britain.
Collaboration extends global reach for Thermo Fisher’s rapid next-generation sequencing technology

Oncocyte Corporation Shares Approach 52-Week Low - Market Mover

12:52pm, Friday, 31'st Dec 2021 Kwhen Finance
Oncocyte Corporation (OCX) shares closed today at 1.0% above its 52 week low of $2.02, giving the company a market cap of $188M. The stock is currently down 14.6% year-to-date, down 16.0% over the past 12 months, and down 71.1% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 201.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 86.0% The company's stock price performance over the past 12 months lags the peer average by 137.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Defender Capital LLC. lifted its holdings in OncoCyte Co. (NYSEAMERICAN:OCX) by 45.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,960,820 shares of the biotechnology company’s stock after acquiring an additional 613,620 shares during the period. OncoCyte accounts for approximately […]

BTIG Research Reiterates Buy Rating for OncoCyte (NYSEAMERICAN:OCX)

07:32pm, Sunday, 19'th Dec 2021 Dakota Financial News
OncoCyte (NYSEAMERICAN:OCX)s stock had its buy rating reiterated by analysts at BTIG Research in a report released on Friday, TipRanks reports. They presently have a $5.00 price objective on the biotechnology companys stock. BTIG Researchs price target would indicate a potential upside of 131.48% from the companys previous close. A number of other research firms []
OncoCyte Corporation (NASDAQ:OCX) price on Friday, December 10, fall -6.28% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.24. A look at the stocks price movement, the close in the last trading session was $2.39, moving within a range at $2.20 and $2.669. The beta value (5-Year Thinking Of Buying OncoCyte Corporation (NASDAQ: OCX) Stock? Heres What You Need To Know Read More »
Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE